EUVIMEDEUVIMED entdecken
Open Access

ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC

Yunhuan Liu, Yong Yu, Congli Hu, Minlin Jiang, Chao Zhao, Xuefei Li, Lei Cheng, Caicun Zhou

Cancer Drug Resistance · 29.05.2025

DOI: 10.20517/cdr.2024.206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Drug Resistance, online erschienen am 29.05.2025. Verfasst von Yunhuan Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of oncology, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment approach for NSCLC. However, the effectiveness of ICI therapy in patients with EGFR-driven NSCLC, particularly those resistant to EGFR-TKI, has been disappointing. The immunosuppressive tumor microenvironment (TME) following EGFR-TKI therapy has been proved to significantly affected the effectiveness of ICIs. Therefore, studying the mechanism behind the development of a suppressive TME and exploring potential interventions is crucial for research on EGFR-TKI-resistant NSCLC.

Methods

ZEB2 levels were quantified in human NSCLC cell lines and in tumor specimens from NSCLC patients by quantitative RT-PCR (qRT-PCR), WB, and immunohistochemical staining. To examine how ZEB2 affected macrophage polarization, M1/M2 marker profiles were measured with qRT-PCR and flow cytometry. Changes in cytokine production triggered by altered ZEB2 expression were determined with qRT-PCR, ELISA, and Meso Scale Discovery electrochemiluminescence assays. The direct binding of ZEB2 to cytokine-gene promoters was tested using a dual-luciferase reporter system. Upstream regulatory pathways were investigated by correlating LUAD transcriptomic data from TCGA with ZEB2 expression and validating key findings via western blotting. Finally, cell-derived xenograft (CDX) models were generated by subcutaneously implanting pre-treated PC9 or HCC827 cells into BALB/c nude mice to verify the impact of EGFR-TKI resistance and ZEB2 on tumor-associated macrophage (TAM) polarization in vivo .

Results

It was elucidated that EGFR-TKI resistance upregulated the M2 polarization biomarkers, Arg-1 (PC9-GR: P < 0.01; HCC827-GR: P < 0.05) and IL4 (PC9-GR: P < 0.01; HCC827-GR: P < 0.01), while downregulated the M1 polarization biomarkers, TNF-α (PC9-GR: P < 0.01; HCC827-GR: P < 0.01), IL1β (PC9-GR: P < 0.01; HCC827-GR: P < 0.01), and IL6(PC9-GR: P < 0.001; HCC827-GR: P < 0.001) in NSCLC cell lines. Meanwhile, CD206+ TAMs (PC9-GR: P < 0.05; HCC827-GR: P < 0.01) were increased and CD86+ TAMs (PC9-GR: P < 0.05; HCC827-GR: P < 0.05) were decreased in both EGFR-TKI-resistant mice models. Apart from the formation of suppressive TME, ZEB2 was found to be upregulated in PC9-GR (qRT-PCR: P < 0.0001; WB: P < 0.05) and HCC827-GR (qRT-PCR: P < 0.0001; WB: P < 0.05) cells. The same trend was also noticed in clinical samples, with ZEB2 upregulated after gefitinib resistance in NSCLC patients (P < 0.0001). Based on these findings, ZEB2 knockdown was proved to downregulate Arg-1 (PC9-GR: P < 0.01; HCC827-GR: P < 0.05) and IL4 (PC9-GR: P < 0.01; HCC827-GR: P < 0.001), while upregulate the TNF-α (PC9-GR: P < 0.0001; HCC827-GR: P < 0.0001), IL1β (HCC827-GR: P < 0.001), and IL6 (PC9-GR: P < 0.01; HCC827-GR: P < 0.001), indicating its role in M1/M2 polarization in both EGFR-TKI-resistant NSCLC cell lines. The downregulation of CD206+ TAMs (PC9-GR: P < 0.05; HCC827-GR: P < 0.01) and the upregulation of CD86+ TAMs (PC9-GR: P < 0.001; HCC827-GR: P < 0.05) also demonstrated the reversion of suppressive TME after ZEB2 knockout in EGFR-TKI-resistant mice models. Additionally, after the intervention of MK2206, which was an Akt inhibitor, ZEB2 expression was suppressed at both low (PC9-GR: P < 0.001; HCC827-GR: P < 0.001) and high concentrations (PC9-GR: P < 0.001; HCC827-GR: P < 0.0001). Finally, the mechanism underlying ZEB2’s regulation on TAM polarization was proved to be associated with cytokine secretion. According to the results of ELISA, apart from its inducement on TGF-β1 secretion (PC9-GR: P < 0.0001; HCC827-GR: P < 0.0001), ZEB2 could directly bind to the promoter region of CSF-1 to elevate its secretion (PC9-GR: P < 0.0001; HCC827-GR: P < 0.0001).

Conclusion

In EGFR-TKI-resistant NSCLC, activation of the PI3K-Akt cascade drove a marked rise in ZEB2 expression. The elevated ZEB2 increased CSF-1 and TGF-β1 release, steering macrophages toward an M2 phenotype while impeding M1 polarization. Accordingly, suppressing ZEB2 had the potential to reshape the TME and enhance the effectiveness of ICIs once EGFR-TKI resistance had emerged.

Schlagwörter

Stichwörter der Autor:innen

EGFR-TKI resistancePI3K-Akt pathwayZEB2immunotherapy resistancetumor microenvironment (TME)tumor-associated macrophages (TAMs)

Autor:innen und Institutionen

  • Department of oncology, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, China.
  • Authors contributed equally.
  • Department of Radiology, Yancheng TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Yancheng 224002, Jiangsu, China.
  • Department of oncology, Shanghai East Hospital Affiliated to Tongji University, No.1800 Yuntai Road, Pudong New District, Shanghai 200120, China.

Zitieren

APA

Liu, Y., Yu, Y., Hu, C., Jiang, M., Zhao, C., Li, X., Cheng, L., & Zhou, C. (2025). ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2024.206

Vancouver

Liu Y, Yu Y, Hu C, Jiang M, Zhao C, Li X, et al. ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC. Cancer Drug Resistance. 2025. doi:10.20517/cdr.2024.206

BibTeX
@article{Liu2025,
  author = {Liu, Yunhuan and Yu, Yong and Hu, Congli and Jiang, Minlin and Zhao, Chao and Li, Xuefei and Cheng, Lei and Zhou, Caicun},
  title = {ZEB2 upregulation modulates the polarization of TAMs toward the immunosuppressive state in EGFR-TKI-resistant NSCLC},
  journal = {Cancer Drug Resistance},
  year = {2025},
  doi = {10.20517/cdr.2024.206}
}
Kostenlos starten →